CAR-T Therapy Moves Into Cancer Prevention, Eli Lilly Closes $3.25B Biotech Acquisition, and Trump's Psychedelics EO Stirs Regulatory Uncertainty
Today's healthcare landscape is defined by three converging forces: therapeutic paradigm shifts, pharma consolidation, and regulatory unpredictability.
Eli Lilly's $3.25 billion acquisition of Kelonia Therapeutics signals continued big pharma appetite for next-generation cell and gene therapy platforms, even f…
The most consequential development is early CAR-T trial data presented at AACR 2026 showing promise in preventing smoldering multiple myeloma from progressing — a conceptual leap from treating active cancer to intercepting it before it fully develops. If validated, this redefines how oncology systems invest in cell therapy infrastructure. Eli Lilly's $3.25 billion acquisition of Kelonia Therapeutics signals continued big pharma appetite for next-generation cell and gene ther…
One pattern. Trace it.
- 01
A pattern worth naming
Watch these indicators over the next 30-90 days: (1) AACR follow-up and peer review of the smoldering myeloma CAR-T data — if additional centers report confirmatory results, expect payer and CMS modeling discussions to begin by Q3 2026; (2) FDA response to Trump's psychedelics EO — look for scheduling changes, new guidance documents, or expanded access pathways within 60 days, particularly for ibogaine in veteran populations; (3) Eli Lilly's integration plan for Kelonia Therapeutics — pipeline reprioritization announcements expected at Lilly's next investor event; (4) PBM transparency litigation trajectory — court rulings in the next 90 days on No Surprises Act-related arbitration cases could materially alter drug pricing structures; (5) GE HealthCare and DeepHealth adoption metrics — early deployment data from community health systems will signal whether AI mammography is crossing from early adopter to mainstream; (6) Pfizer's next strategic hire or reorganization — the speed of replacing Baum's role will indicate whether the company is pivoting strategy or doubling down on its current path.
“If CAR-T shifts to high-risk prevention like the AACR data suggests, do we have the infusion capacity and referral volume to justify our current cell therapy build-out?”
Ask your CFO whether the unit economics on every new service line still pencil under the new rate environment.
By Joseph Lancaster, Editor — with research from Pine Needle's intelligence layer.
The next argument lands tomorrow at 6 a.m. Pacific. Get it in your inbox →